Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer

Affiliations

¹ Google, Mountain View, California.
² Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts.
³ Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

Comment

Zachary R McCaw et al. JAMA Oncol. 2020.

. 2020 Aug 1;6(8):1301-1302.

doi: 10.1001/jamaoncol.2020.2256.

¹ Google, Mountain View, California.
² Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts.
³ Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

No abstract available

Comment in

Risk-Benefit Comparisons Between Shorter and Longer Durations of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer-Reply.
Zaniboni A, Petrelli F, Labianca R. Zaniboni A, et al. JAMA Oncol. 2020 Aug 1;6(8):1302-1303. doi: 10.1001/jamaoncol.2020.2262. JAMA Oncol. 2020. PMID: 32584370 No abstract available.

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F, Labianca R, Zaniboni A, Lonardi S, Galli F, Rulli E, Rosati G, Corallo S, Ronzoni M, Cardellino GG, Mattioli R, Mambrini A, Ciuffreda L, Banzi M, Pusceddu V, Maiello E, Zampino M, Zagonel V, Marchetti P, Corsi D, Rimassa L, Cinieri S, Sobrero A. Petrelli F, et al. JAMA Oncol. 2020 Apr 1;6(4):547-551. doi: 10.1001/jamaoncol.2019.6486. JAMA Oncol. 2020. PMID: 32053133 Free PMC article. Clinical Trial.